control group:PERJETA
Sponsors
Affiliated Hospital of Qingdao University
Conditions
Breast cancer
Phase 1
A single center, randomized, double-blind, parallel controlled phase I clinical trial comparing the pharmacokinetic and safety similarities of recombinant humanized anti-Human epidermal growth factor receptor monoclonal antibody injection (HS627) with PERJETA after a single dose administration in healthy male subjects
Active, not recruitingChiCTR2100042105
Start: 2020-09-01Updated: 2022-04-19
Single Center, Randomized, Double-blind, Parallel Controlled Phase I Clinical Trial Comparing the Pharmacokinetic and Safety Similarities of Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody Injection (HS627)(2 Kinds Of Specification)with PERJETA after a Single Dose Intravenous in Dripping in Healthy
Active, not recruitingChiCTR2200058301
Start: 2022-03-27Updated: 2023-12-19